Oncolytics Biotech Inc. – NASDAQ:ONCY
Oncolytics Biotech stock price today
$1
+0.00
+0.62%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Oncolytics Biotech stock price monthly change
-4.42%
month
Oncolytics Biotech stock price quarterly change
-4.42%
quarter
Oncolytics Biotech stock price yearly change
-18.19%
year
Oncolytics Biotech key metrics
Market Cap | 66.00M |
Enterprise value | 55.11M |
P/E | -3.56 |
EV/Sales | N/A |
EV/EBITDA | -2.31 |
Price/Sales | N/A |
Price/Book | 3.15 |
PEG ratio | -0.63 |
EPS | -0.40 |
Revenue | N/A |
EBITDA | -35.67M |
Income | -28.20M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOncolytics Biotech stock price history
Oncolytics Biotech stock forecast
Oncolytics Biotech financial statements
| Jun 2023 | 0 | -7.44M | |
|---|---|---|---|
| Sep 2023 | 0 | -9.92M | |
| Dec 2023 | 0 | -3.94M | |
| Mar 2024 | 0 | -6.89M |
| Dec 2023 | 0 | -3.94M | |
|---|---|---|---|
| Mar 2024 | 0 | -6.89M | |
| Sep 2025 | 0 | -8.43M | |
| Dec 2025 | 0 | -7.69M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 31966000 | 9.72M | 30.43% |
|---|---|---|---|
| Sep 2023 | 46089000 | 17.07M | 37.04% |
| Dec 2023 | 38820000 | 11.25M | 29% |
| Mar 2024 | 34750000 | 11.78M | 33.9% |
| Jun 2023 | -8.46M | 6.79M | 3.69M |
|---|---|---|---|
| Sep 2023 | -6.03M | 6.76M | 21.28M |
| Dec 2023 | -6.12M | -3K | 1.74M |
| Mar 2024 | -7.46M | -46K | 1.49M |
Oncolytics Biotech alternative data
| Aug 2023 | 29 |
|---|---|
| Sep 2023 | 29 |
| Oct 2023 | 29 |
| Nov 2023 | 29 |
| Dec 2023 | 29 |
| Jan 2024 | 29 |
| Feb 2024 | 29 |
| Mar 2024 | 29 |
| Apr 2024 | 29 |
| May 2024 | 29 |
| Jun 2024 | 29 |
| Jul 2024 | 29 |
Oncolytics Biotech other data
1.41%
-0.27%
of ONCY is owned by hedge funds
815.61K
-81.53K
shares is hold by hedge funds
| Patent |
|---|
Application Filling date: 21 Feb 2020 Issue date: 7 Apr 2022 |
Grant Utility: Reoviruses having modified sequences Filling date: 13 Feb 2020 Issue date: 15 Feb 2022 |
Application Filling date: 13 Feb 2020 Issue date: 30 Jul 2020 |
Grant Utility: Reoviruses having modified sequences Filling date: 3 Jul 2018 Issue date: 24 Mar 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 9 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 3 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 14 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Andrew R. de Guttadauro (1967) Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc | $378,080 |
-
What's the price of Oncolytics Biotech stock today?
One share of Oncolytics Biotech stock can currently be purchased for approximately $1.
-
When is Oncolytics Biotech's next earnings date?
Unfortunately, Oncolytics Biotech's (ONCY) next earnings date is currently unknown.
-
Does Oncolytics Biotech pay dividends?
No, Oncolytics Biotech does not pay dividends.
-
How much money does Oncolytics Biotech make?
Oncolytics Biotech has a market capitalization of 66.00M.
-
What is Oncolytics Biotech's stock symbol?
Oncolytics Biotech Inc. is traded on the NASDAQ under the ticker symbol "ONCY".
-
What is Oncolytics Biotech's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Oncolytics Biotech?
Shares of Oncolytics Biotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Oncolytics Biotech's key executives?
Oncolytics Biotech's management team includes the following people:
- Mr. Andrew R. de Guttadauro Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc(age: 58, pay: $378,080)
-
How many employees does Oncolytics Biotech have?
As Jul 2024, Oncolytics Biotech employs 29 workers.
-
When Oncolytics Biotech went public?
Oncolytics Biotech Inc. is publicly traded company for more then 23 years since IPO on 5 Oct 2001.
-
What is Oncolytics Biotech's official website?
The official website for Oncolytics Biotech is oncolyticsbiotech.com.
-
Where are Oncolytics Biotech's headquarters?
Oncolytics Biotech is headquartered at 322 11th Avenue SW, Calgary, AB.
-
How can i contact Oncolytics Biotech?
Oncolytics Biotech's mailing address is 322 11th Avenue SW, Calgary, AB and company can be reached via phone at +1 403 670 7380.
Oncolytics Biotech company profile:
Oncolytics Biotech Inc.
oncolyticsbiotech.comExchange:
NASDAQ
Full time employees:
29
Industry:
Biotechnology
Sector:
Healthcare
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
322 11th Avenue SW
Calgary, AB T2R 0C5
Calgary, AB T2R 0C5
CIK: 0001129928
ISIN: CA6823108759
CUSIP: 682310875
